LadRx Corporation (LADX)
USD 1.49
(-2.61%)
USD 1.49
(-2.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.03 Million USD | -77.8% |
| 2022 | -1.14 Million USD | 81.97% |
| 2021 | -6.35 Million USD | 32.45% |
| 2020 | -9.4 Million USD | 41.68% |
| 2019 | -16.13 Million USD | 24.53% |
| 2018 | -21.37 Million USD | 20.97% |
| 2017 | -27.04 Million USD | 18.03% |
| 2016 | -32.99 Million USD | -48.21% |
| 2015 | -22.26 Million USD | 30.91% |
| 2014 | -32.21 Million USD | -180.58% |
| 2013 | -11.48 Million USD | 19.95% |
| 2012 | -14.34 Million USD | 20.26% |
| 2011 | -17.98 Million USD | -184.43% |
| 2010 | -6.32 Million USD | 36.08% |
| 2009 | -9.89 Million USD | 60.49% |
| 2008 | -25.04 Million USD | 50.41% |
| 2007 | -50.49 Million USD | -66.21% |
| 2006 | -30.38 Million USD | -266.07% |
| 2005 | -8.29 Million USD | -317.56% |
| 2004 | -1.98 Million USD | 82.93% |
| 2003 | -11.64 Million USD | -2906.46% |
| 2002 | -387.31 Thousand USD | 92.65% |
| 2001 | -5.27 Million USD | -39.52% |
| 2000 | -3.77 Million USD | -58.66% |
| 1999 | -2.38 Million USD | 73.24% |
| 1998 | -8.9 Million USD | -128.21% |
| 1997 | -3.9 Million USD | -143.75% |
| 1996 | -1.6 Million USD | 90.36% |
| 1995 | -16.6 Million USD | -388.24% |
| 1994 | -3.4 Million USD | 50.72% |
| 1993 | -6.9 Million USD | -50.0% |
| 1992 | -4.6 Million USD | 79.74% |
| 1991 | -22.7 Million USD | -2422.22% |
| 1990 | -900 Thousand USD | -134.62% |
| 1989 | 2.6 Million USD | 148.15% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.06 Million USD | -1.36% |
| 2024 Q2 | -816.56 Thousand USD | 60.44% |
| 2023 FY | -2.03 Million USD | -77.8% |
| 2023 Q3 | -2.84 Million USD | 17.88% |
| 2023 Q1 | -424.29 Thousand USD | 62.96% |
| 2023 Q4 | -2.03 Million USD | 28.54% |
| 2023 Q2 | -3.47 Million USD | -717.9% |
| 2022 Q4 | -1.14 Million USD | 58.19% |
| 2022 FY | -1.14 Million USD | 81.97% |
| 2022 Q1 | -4.7 Million USD | 25.88% |
| 2022 Q2 | -3.78 Million USD | 19.54% |
| 2022 Q3 | -2.73 Million USD | 27.71% |
| 2021 FY | -6.35 Million USD | 32.45% |
| 2021 Q2 | -7.92 Million USD | 9.6% |
| 2021 Q3 | -15.99 Million USD | -101.78% |
| 2021 Q1 | -8.77 Million USD | 6.77% |
| 2021 Q4 | -6.35 Million USD | 60.28% |
| 2020 Q1 | -14.57 Million USD | 9.63% |
| 2020 FY | -9.4 Million USD | 41.68% |
| 2020 Q2 | -13.9 Million USD | 4.61% |
| 2020 Q3 | -11.96 Million USD | 13.97% |
| 2020 Q4 | -9.4 Million USD | 21.36% |
| 2019 FY | -16.13 Million USD | 24.53% |
| 2019 Q3 | -8.49 Million USD | 56.18% |
| 2019 Q1 | -9.01 Million USD | 57.82% |
| 2019 Q2 | -19.37 Million USD | -114.93% |
| 2019 Q4 | -16.13 Million USD | -89.96% |
| 2018 FY | -21.37 Million USD | 20.97% |
| 2018 Q1 | -25.08 Million USD | 7.22% |
| 2018 Q4 | -21.37 Million USD | 13.36% |
| 2018 Q2 | -27.04 Million USD | -7.8% |
| 2018 Q3 | -24.66 Million USD | 8.79% |
| 2017 Q4 | -27.04 Million USD | 22.61% |
| 2017 Q3 | -34.94 Million USD | -7.65% |
| 2017 Q2 | -32.45 Million USD | -35.61% |
| 2017 Q1 | -23.93 Million USD | 27.45% |
| 2017 FY | -27.04 Million USD | 18.03% |
| 2016 Q4 | -32.99 Million USD | 6.04% |
| 2016 Q1 | -44.71 Million USD | -100.87% |
| 2016 Q2 | -32.32 Million USD | 27.71% |
| 2016 Q3 | -35.11 Million USD | -8.63% |
| 2016 FY | -32.99 Million USD | -48.21% |
| 2015 FY | -22.26 Million USD | 30.91% |
| 2015 Q1 | -28.05 Million USD | 12.93% |
| 2015 Q3 | -55.77 Million USD | -43.64% |
| 2015 Q2 | -38.83 Million USD | -38.43% |
| 2015 Q4 | -22.26 Million USD | 60.09% |
| 2014 Q3 | -39.41 Million USD | 24.01% |
| 2014 Q1 | -62.02 Million USD | -440.17% |
| 2014 Q4 | -32.21 Million USD | 18.25% |
| 2014 FY | -32.21 Million USD | -180.58% |
| 2014 Q2 | -51.86 Million USD | 16.38% |
| 2013 Q2 | -10.98 Million USD | 3.93% |
| 2013 FY | -11.48 Million USD | 19.95% |
| 2013 Q1 | -11.42 Million USD | 20.32% |
| 2013 Q4 | -11.48 Million USD | -90.24% |
| 2013 Q3 | -6.03 Million USD | 45.03% |
| 2012 Q3 | -12.45 Million USD | -5.01% |
| 2012 Q1 | -16.91 Million USD | 5.96% |
| 2012 FY | -14.34 Million USD | 20.26% |
| 2012 Q4 | -14.34 Million USD | -15.18% |
| 2012 Q2 | -11.85 Million USD | 29.9% |
| 2011 FY | -17.98 Million USD | -184.43% |
| 2011 Q3 | -30.38 Million USD | -332.68% |
| 2011 Q2 | -7.02 Million USD | 36.17% |
| 2011 Q1 | -11 Million USD | -73.97% |
| 2011 Q4 | -17.98 Million USD | 40.8% |
| 2010 Q3 | -10.15 Million USD | 18.42% |
| 2010 Q4 | -6.32 Million USD | 37.75% |
| 2010 Q1 | -10.71 Million USD | -8.26% |
| 2010 FY | -6.32 Million USD | 36.08% |
| 2010 Q2 | -12.45 Million USD | -16.26% |
| 2009 Q3 | -7.76 Million USD | -11.87% |
| 2009 FY | -9.89 Million USD | 60.49% |
| 2009 Q1 | -21.9 Million USD | 12.54% |
| 2009 Q2 | -6.94 Million USD | 68.3% |
| 2009 Q4 | -9.89 Million USD | -27.38% |
| 2008 FY | -25.04 Million USD | 50.41% |
| 2008 Q2 | -36.38 Million USD | 16.44% |
| 2008 Q4 | -25.04 Million USD | 18.99% |
| 2008 Q3 | -30.91 Million USD | 15.03% |
| 2008 Q1 | -43.53 Million USD | 13.78% |
| 2007 Q4 | -50.49 Million USD | 7.13% |
| 2007 Q1 | -36.35 Million USD | -19.65% |
| 2007 FY | -50.49 Million USD | -66.21% |
| 2007 Q2 | -69.69 Million USD | -91.73% |
| 2007 Q3 | -54.37 Million USD | 21.98% |
| 2006 Q2 | -13.24 Million USD | 22.49% |
| 2006 FY | -30.38 Million USD | -266.07% |
| 2006 Q1 | -17.08 Million USD | -105.87% |
| 2006 Q3 | -33.7 Million USD | -154.54% |
| 2006 Q4 | -30.38 Million USD | 9.87% |
| 2005 Q1 | -19.52 Million USD | -882.21% |
| 2005 Q2 | -15.77 Million USD | 19.21% |
| 2005 Q3 | -11.21 Million USD | 28.91% |
| 2005 FY | -8.29 Million USD | -317.56% |
| 2005 Q4 | -8.29 Million USD | 25.98% |
| 2004 FY | -1.98 Million USD | 82.93% |
| 2004 Q1 | -10 Million USD | 14.08% |
| 2004 Q4 | -1.98 Million USD | 55.2% |
| 2004 Q2 | -7.1 Million USD | 29.0% |
| 2004 Q3 | -4.43 Million USD | 37.54% |
| 2003 Q3 | -13.09 Million USD | -123.73% |
| 2003 Q4 | -11.64 Million USD | 11.06% |
| 2003 FY | -11.64 Million USD | -2906.46% |
| 2003 Q1 | -1.28 Million USD | -230.7% |
| 2003 Q2 | -5.85 Million USD | -356.92% |
| 2002 Q2 | -4.29 Million USD | 13.91% |
| 2002 FY | -387.31 Thousand USD | 92.65% |
| 2002 Q3 | -2.12 Million USD | 50.5% |
| 2002 Q1 | -4.98 Million USD | 5.39% |
| 2002 Q4 | -387.31 Thousand USD | 81.78% |
| 2001 Q1 | -2.84 Million USD | 24.71% |
| 2001 FY | -5.27 Million USD | -39.52% |
| 2001 Q4 | -5.27 Million USD | -180.91% |
| 2001 Q3 | -1.87 Million USD | 9.03% |
| 2001 Q2 | -2.06 Million USD | 27.48% |
| 2000 Q4 | -3.77 Million USD | -73.94% |
| 2000 Q3 | -2.17 Million USD | 8.48% |
| 2000 FY | -3.77 Million USD | -58.66% |
| 2000 Q1 | -3.21 Million USD | -35.16% |
| 2000 Q2 | -2.37 Million USD | 26.26% |
| 1999 Q2 | -10 Million USD | 19.35% |
| 1999 FY | -2.38 Million USD | 73.24% |
| 1999 Q3 | -5.4 Million USD | 46.0% |
| 1999 Q1 | -12.4 Million USD | -39.33% |
| 1999 Q4 | -2.38 Million USD | 55.89% |
| 1998 Q4 | -8.9 Million USD | 33.58% |
| 1998 Q3 | -13.4 Million USD | 10.67% |
| 1998 Q1 | -4.5 Million USD | -15.38% |
| 1998 Q2 | -15 Million USD | -233.33% |
| 1998 FY | -8.9 Million USD | -128.21% |
| 1997 Q2 | -4.8 Million USD | -20.0% |
| 1997 Q4 | -3.9 Million USD | 37.1% |
| 1997 Q1 | -4 Million USD | -150.0% |
| 1997 FY | -3.9 Million USD | -143.75% |
| 1997 Q3 | -6.2 Million USD | -29.17% |
| 1996 FY | -1.6 Million USD | 90.36% |
| 1996 Q4 | -1.6 Million USD | -60.0% |
| 1996 Q1 | -3 Million USD | 81.93% |
| 1996 Q2 | -2.5 Million USD | 16.67% |
| 1996 Q3 | -1 Million USD | 60.0% |
| 1995 Q2 | -23.8 Million USD | -2875.0% |
| 1995 Q4 | -16.6 Million USD | 30.83% |
| 1995 Q1 | -800 Thousand USD | 76.47% |
| 1995 FY | -16.6 Million USD | -388.24% |
| 1995 Q3 | -24 Million USD | -0.84% |
| 1994 Q2 | -1 Million USD | 62.96% |
| 1994 Q1 | -2.7 Million USD | 60.87% |
| 1994 Q4 | -3.4 Million USD | -326.67% |
| 1994 FY | -3.4 Million USD | 50.72% |
| 1994 Q3 | 1.5 Million USD | 250.0% |
| 1993 Q1 | -5.4 Million USD | -17.39% |
| 1993 Q2 | -5.1 Million USD | 5.56% |
| 1993 Q4 | -6.9 Million USD | 43.9% |
| 1993 Q3 | -12.3 Million USD | -141.18% |
| 1993 FY | -6.9 Million USD | -50.0% |
| 1992 Q1 | -33.8 Million USD | -48.9% |
| 1992 Q4 | -4.6 Million USD | 65.41% |
| 1992 Q2 | -13.4 Million USD | 60.36% |
| 1992 Q3 | -13.3 Million USD | 0.75% |
| 1992 FY | -4.6 Million USD | 79.74% |
| 1991 Q3 | -3.8 Million USD | -40.74% |
| 1991 FY | -22.7 Million USD | -2422.22% |
| 1991 Q1 | -1.1 Million USD | -22.22% |
| 1991 Q2 | -2.7 Million USD | -145.45% |
| 1991 Q4 | -22.7 Million USD | -497.37% |
| 1990 Q1 | -1 Million USD | -138.46% |
| 1990 Q3 | -900 Thousand USD | -80.0% |
| 1990 Q4 | -900 Thousand USD | 0.0% |
| 1990 Q2 | -500 Thousand USD | 50.0% |
| 1990 FY | -900 Thousand USD | -134.62% |
| 1989 FY | 2.6 Million USD | 148.15% |
| 1989 Q4 | 2.6 Million USD | 966.67% |
| 1989 Q3 | -300 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -155355.649% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 136.054% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 104.759% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -715.828% |
| Rebus Holdings, Inc. | 305 Thousand USD | 767.695% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 67.698% |
| Qrons Inc. | 351.42 Thousand USD | 679.486% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 427.215% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 104.689% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -9878.778% |
| Skye Bioscience, Inc. | -5.72 Million USD | 64.406% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 112.919% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 149.453% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 606.775% |
| SQZ Biotechnologies Company | -36.23 Million USD | 94.38% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 190.823% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 319.64% |
| Mesoblast Limited | 55.85 Million USD | 103.646% |
| Marizyme, Inc. | 18.56 Million USD | 110.967% |
| Genus plc | 190.6 Million USD | 101.068% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 191.083% |
| Pharming Group N.V. | 109.8 Million USD | 101.855% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 336.732% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 267.764% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 399.481% |
| ContraFect Corporation | -6.02 Million USD | 66.205% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1612.54% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 276.252% |
| IMV Inc. | 7.67 Million USD | 126.549% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 137.014% |
| MultiCell Technologies, Inc. | 90.04 USD | 2261838.116% |
| ONE Bio Corp. | 9.04 Million USD | 122.527% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -177.456% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 115.73% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 248.868% |
| Q BioMed Inc. | 4.06 Million USD | 150.159% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 106.665% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 302.088% |
| Biomind Labs Inc. | 711.4 Thousand USD | 386.261% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 103.364% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 201.854% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 115.902% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 666.142% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1556.66% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 10350.511% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 192.483% |
| GB Sciences, Inc. | 1.74 Million USD | 216.548% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1008.053% |
| HST Global, Inc. | 96.79 Thousand USD | 2203.942% |
| CSL Limited | 10.52 Billion USD | 100.019% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 1087.537% |
| Halberd Corporation | 144.72 Thousand USD | 1507.169% |
| Enzolytics Inc. | 981.65 Thousand USD | 307.452% |
| Agentix Corp. | 37.63 Thousand USD | 5511.679% |
| Resverlogix Corp. | 6.45 Million USD | 131.568% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -202.556% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.9% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 95.668% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 128.8% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 175.185% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 76.963% |
| AVAX Technologies, Inc. | -5.9 Million USD | 65.502% |
| Zenith Capital Corp. | 10.06 Thousand USD | 20335.185% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.808% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1116.04% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 185.35% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1337.907% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -11017.311% |
| Kadimastem Ltd | -253.1 Thousand USD | -704.604% |
| Helix BioMedix, Inc. | -2.57 Million USD | 20.761% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 110.044% |
| BioStem Technologies, Inc. | 4.47 Million USD | 145.538% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1111.89% |
| Cell Source, Inc. | 9.23 Million USD | 122.059% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 420.619% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 420.619% |
| NovAccess Global Inc. | 2.17 Million USD | 193.482% |
| Affymax, Inc. | -5.59 Million USD | 63.615% |
| Itoco Inc. | 228.3 Thousand USD | 991.995% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1597.525% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 141.083% |
| Mobile Lads Corp. | 484.23 Thousand USD | 520.556% |
| CytoDyn Inc. | 20.26 Million USD | 110.051% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -314655.641% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -21872.317% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 126.427% |
| SYBLEU INC | 473.71 Thousand USD | 529.894% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 145.691% |
| International Stem Cell Corporation | 2.59 Million USD | 178.628% |
| Bioxytran, Inc. | 1.89 Million USD | 207.244% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 3362.892% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 193.377% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 159.303% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 123.81% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 363.584% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -62.918% |
| Neutra Corp. | 52.18 Thousand USD | 4002.253% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 18.181% |
| PureTech Health plc | -167.19 Million USD | 98.782% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -731.524% |
| IXICO plc | -4.44 Million USD | 54.181% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 115.406% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 103.713% |
| CSL Limited | 10.52 Billion USD | 100.019% |
| Cellectis S.A. | -43.81 Million USD | 95.353% |